SCHEDULE: Arcellx to be Acquired by Gilead for $115 Cash Plus CVR

New Enterprise Associates and other major stockholders agree to tender shares in Arcellx's acquisition by Gilead Sciences for $115 cash and a $5 CVR per share.

Summary

• Arcellx, Inc. has entered into an Agreement and Plan of Merger with Gilead Sciences, Inc. and its subsidiary, Ravens Sub, Inc.
• Gilead's subsidiary will commence a tender offer to acquire all outstanding shares of Arcellx Common Stock.
• The offer price is $115.00 per share in cash, plus one contractual contingent value right (CVR) worth $5.00 in cash upon achievement of a specified milestone.
• New Enterprise Associates 15, L.P. (NEA 15) and other stockholders have entered into Support Agreements with Gilead, agreeing to tender their shares and vote against alternative acquisition proposals.
• NEA 15, NEA Partners 15, L.P., NEA 15 GP, LLC, and managers Forest Baskett, Anthony A. Florence, Jr., Mohamad H. Makhzoumi, and Scott D. Sandell collectively beneficially own approximately 5.3% of Arcellx's common stock.
• The beneficial ownership for most reporting persons is 3,045,262 shares, while Scott D. Sandell beneficially owns 3,055,360 shares.
• The percentage of class represented by these holdings is calculated based on 57,822,871 shares outstanding as of October 31, 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development for Arcellx shareholders, as it provides a clear and substantial return on investment through a definitive acquisition agreement, including both a cash component and potential upside from a CVR.

Positives

• The merger agreement provides a clear path for Arcellx shareholders to receive a fixed cash payment of $115.00 per share.
• Shareholders also stand to receive an additional $5.00 per share via a Contingent Value Right (CVR) upon the achievement of a specified milestone, offering potential upside.
• Major stockholders, including New Enterprise Associates, have committed to supporting the transaction by entering into Tender and Support Agreements, indicating strong insider alignment with the deal.

Risks

• The Support Agreements, and thus the commitment of major stockholders, will automatically terminate upon certain events, including the termination of the Merger Agreement, which could jeopardize the transaction.
• The contingent payment of $5.00 per CVR is dependent on the achievement of a specified milestone, meaning the full $120.00 per share value is not guaranteed.

Future Outlook

The primary future outlook is the consummation of the tender offer and subsequent merger of Arcellx into a subsidiary of Gilead Sciences, Inc. The reporting persons may dispose of or acquire additional shares depending on market conditions and their ongoing evaluation of Arcellx's business and prospects, but no other specific plans for corporate transactions or changes are currently in place.

Industry Context

StockSavvy.ai notes that this acquisition aligns with a broader industry trend where larger pharmaceutical companies like Gilead Sciences seek to bolster their pipelines and market presence by acquiring innovative biotechnology firms such as Arcellx. This strategy is particularly prevalent in high-growth therapeutic areas, allowing established players to integrate promising new technologies and drug candidates, often through structures involving upfront cash and performance-based contingent payments.

Comparison to Industry Standards

• The acquisition structure, combining a fixed cash payment with a Contingent Value Right (CVR), is a common mechanism in the biotechnology and pharmaceutical sectors. This approach allows the acquirer (Gilead) to mitigate risk by tying a portion of the acquisition cost to the successful achievement of specific clinical or regulatory milestones, while providing target shareholders (Arcellx) with potential upside beyond the immediate cash offer.
• Comparable transactions often include CVRs for late-stage clinical assets or regulatory approvals. For example, similar structures have been seen in acquisitions like Bristol Myers Squibb's acquisition of MyoKardia or Sanofi's acquisition of Synthorx, where milestone payments were crucial components of the deal value.
• The 5.3% beneficial ownership by New Enterprise Associates and its affiliates is a significant stake, and their agreement to tender shares provides strong support for the transaction, which is typical for major institutional investors in such deals.

Corporate Governance

Related Party Transactions

• New Enterprise Associates 15, L.P. and its affiliated entities and managers, who are significant beneficial owners of Arcellx stock, entered into Tender and Support Agreements with Gilead Sciences, Inc. in connection with the merger.

Stakeholder Impact

• Shareholders: Will receive $115.00 per share in cash and one CVR for $5.00 upon milestone achievement, representing a significant return on their investment.
• Employees: The merger will likely lead to integration into Gilead Sciences, which could result in changes to employment terms, roles, or potential redundancies, though the filing does not specify details.
• Customers/Partners: The acquisition by a larger pharmaceutical company like Gilead could lead to expanded resources and reach for Arcellx's products/pipeline, potentially benefiting future customers and partners.

Next Steps

• Purchaser (Ravens Sub, Inc.) will commence a tender offer to acquire all issued and outstanding shares of Arcellx Common Stock.
• Following the consummation of the tender offer, Purchaser will merge with and into Arcellx, with Arcellx being the surviving corporation.

Key Dates

Recommendation

Given the definitive merger agreement with a fixed cash price and a contingent value right, the primary upside for existing shareholders is capped at the offer price plus the CVR. For investors seeking to realize the acquisition value, holding the shares until the tender offer closes is the appropriate strategy. New purchases would primarily be for arbitrage, assuming the market price is below the offer price, but for a general investment recommendation, 'hold' is suitable as the company is being acquired.

Keywords

Arcellx, Gilead Sciences, Merger Agreement, Tender Offer, Contingent Value Right, CVR, New Enterprise Associates, Schedule 13D, Acquisition, Biotechnology, Pharmaceuticals